{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifds5kr54udo5c5vnltunhd3e72agilml5bik72bql7ljr5usp72e",
    "uri": "at://did:plc:scbtcug7owbatifs7ovdsyiw/app.bsky.feed.post/3mem24s7m33v2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigjwjhzdv7lblonzshrnybdoruuf6xvuhmtas56ulrho7shvk53wi"
    },
    "mimeType": "image/jpeg",
    "size": 267876
  },
  "path": "/media/novo-ceo-blasts-mass-compounding-glp-1-drugs-safety-battle-escalates",
  "publishedAt": "2026-02-11T17:25:35.000Z",
  "site": "https://www.foxbusiness.com",
  "tags": [
    "1cb0011a-404d-574d-a307-10d57d660275",
    "fbn",
    "Fox Business",
    "fox-business/media",
    "fox-business/shows/mornings-with-maria",
    "fox-news/fox-news-health/fox-news-healthy-living/fox-news-medications",
    "fox-business/media",
    "article"
  ],
  "textContent": "Novo Nordisk’s CEO says compounded GLP-1 knockoffs sourced from overseas ingredients could endanger patients and undermine FDA oversight as legal battle escalates.",
  "title": "Novo CEO blasts ‘mass compounding’ of GLP-1 drugs as safety battle escalates"
}